Nothing comparable since the round — shown at its later-stage round, Oct 2025 ($386.9M post-money).
- ·13 fund marks: filer, period, implied $/share
Membership and data by Private Market View
Valuation timeline
0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026Membership and data by Private Market View
Hemab Therapeutics Holdings funding history
2 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Oct 2025 | Later Stage VC (Series C) | $157.0M | ▮ | ▮ |
| Feb 2023 | Early Stage VC (Series B) | $137.8M | ▮ | ▮ |
Membership and data by Private Market View
Hemab Therapeutics Holdings valuation
Hemab Therapeutics Holdings is valued at approximately $387 million as of Oct 2026. The figure is set by institutional fund marks. The reference point is its later-stage round in Oct 2025, at a $387 million post-money valuation.
Recent activity
In the last 90 days, Hemab Therapeutics Holdings's record added 8 institutional fund marks (latest period Jul 2026).
How much has Hemab Therapeutics Holdings raised?
Hemab Therapeutics Holdings has raised $355 million across 2 recorded rounds since 2023. The largest was a $157 million Series C in Oct 2025.
Institutional holders and vehicles
5 SEC-registered funds reported 13 fair-value marks on Hemab Therapeutics Holdings between May 2026 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: CORXEL Pharmaceuticals ($475 million), Diagonal Therapeutics ($459 million) and AgomAb ($416 million).
How Hemab Therapeutics Holdings's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Hemab Therapeutics Holdings, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by institutional fund marks. Question about this number? Full methodology →
Frequently asked about Hemab Therapeutics Holdings
- What is Hemab Therapeutics Holdings worth?
- Hemab Therapeutics Holdings is valued at $386.9M as of Oct 2026. Nothing comparable since the round — shown at its later-stage round, Oct 2025 ($386.9M post-money).
- How much has Hemab Therapeutics Holdings raised?
- Hemab Therapeutics Holdings has raised $355.1M in total funding across 2 recorded rounds.
- When did Hemab Therapeutics Holdings last raise?
- Hemab Therapeutics Holdings last raised in Oct 2025 (Later Stage VC (Series C)), raising $157.0M.